PDCD1 and neoplasm: Although IgG1-triggered effector functions such as ADCC, complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) contribute to the antitumor activities by trastuzumab, they can cause collateral damage to PD-1-expressing immune cells, especially tumor-infiltrating T cells.